Clinical Trials Browser

Prostatic Neoplasms

Lung Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Sarcoma, Kaposi

Liposarcoma, Neoplasms, Sarcoma

Prostatic Neoplasms

Brain Neoplasms, Carcinoma, Renal Cell

Glioblastoma

Pancreatic Neoplasms

Prostatic Neoplasms

Triple Negative Breast Neoplasms

Glioblastoma

Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Colorectal Neoplasms

Colonic Neoplasms

Multiple Myeloma

Advanced Endometrial Cancer

First-line Non-small-cell Lung Cancer

Thyroid Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Carcinoma, Transitional Cell

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

Squamous Cell Carcinoma of Head and Neck

Cardiovascular Diseases, Hematologic Diseases, Immune System Diseases, Multiple Myeloma, Neoplasms

Triple Negative Breast Neoplasms

Brain Neoplasms, Triple Negative Breast Neoplasms

Squamous Cell Carcinoma of Head and Neck, Melanoma

Endometrial Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Renal Cell

Multiple Myeloma

Carcinoma, Non-Small-Cell Lung

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Transitional Cell

Colorectal Neoplasms

Head and Neck Neoplasms

Metastatic HPV-16 Positive Squamous Cell Anal Cancer

Carcinoma, Neuroendocrine

Endometrial Neoplasms

Head and Neck Neoplasms

Neoplasms, Hematologic Neoplasms

Pancreatic Neoplasms

Metastatic Bladder Urothelial Carcinoma

Clinical Trials

PEM-PRO

Perioperative Immunotherapy for NSCLC (ECTOP-1030)

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

MK-5890-003

PULSAR

NeoSarc

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases

Abemaciclib + Pembrolizumab In Glioblastoma

PRIMUS006

TALON

SOC-2320

Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer

Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)

ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases

Pembrolizumab in Early Stage Colon Cancer

Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy

GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer

Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer

PELICAN

CARMA

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer

A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

AdvanTIG-211

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients

Sargramostim (GM-CSF) + PD-1

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC

Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib

Study of Dara-Pembro for Multiple Myeloma Patients

HFHS 21-01

Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer

Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer

Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor

Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer

SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer

Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma

PECULIAR

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma

Pembrolizumab With Axitinib in Recurrent Endometrial Cancer

AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma

Dual PD-1 and JAK2 Inhibition in Hematological Malignancies

Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy